secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2022-03-08T23:59:59+00:00
Accession:  0001193125-22-068757
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Therapeutics reports Q4 2021 net loss $19.3M; first patient dosed in MGTA-117 trial
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities at Dec 31, 2021: $176.9M, expected to fund operations into Q4 2023.
- First patient dosed and completed initial safety assessment in Phase 1/2 trial of MGTA-117 targeted conditioning; data expected in 2022.
- IND-enabling studies initiated for CD45-ADC; dose-ranging toxicology results anticipated in H2 2022.
- MGTA-145 stem cell mobilization program advancing in sickle cell disease; data expected in H2 2022.
- Net loss of $19.3M for Q4 2021 vs. $18.2M in Q4 2020; R&D expenses increased to $13.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522068757/0001193125-22-068757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522068757/d682941d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-068757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer